GZMB and neoplasm: To overcome the limitations of 18F-FDG (Figure 1), we explored the potential of 68Ga-grazytracer PET to distinguish tumor pseudoprogression from true progression via noninvasive imaging of granzyme B released by functional CTLs during ICI therapy.